Tuesta LM, Chen Z, Duncan A, Fowler CD, Ishikawa M, Lee BR, et al
For each, we favor low starting doses, short cycles (often 1014 days for an initial trial), and careful symptom monitoring
HARD-WORKING Mr
Disclosures: Yi-Hsiang Huang: Nothing to Disclose, Ming-Han Chen: Nothing to Disclose, ChiehJu Lee: Nothing to Disclose, Wei-Sheng Chen: Nothing to Disclose, Chang-Te Chou: Nothing to Disclose 784 PREVALENCE AND CHARACTERISTICS OF HIGH-RISK FIB-4 AMONG PRIMARY CARE PATIENTS WITH PRE-DIABETES (PREDM): POTENTIAL TO IMPROVE THE CURRENT STATE OF DISEASE UNDER-RECOGNITION Max Goldman 1 Janet Chu 2 Nghiem Ha 2 Bilal Hameed 2 Mandana Khalili 2 Rena Fox 2 , 1 Kaiser Permanente, Northern California, 2 University of California, San Francisco Background: AASLD guidelines recommend that primary care (PC) patients with any risk factor for MASLD be regularly assessed with FIB-4, with further evaluation recommended for those with indeterminate- or high-risk scores
Comparative analysis of oral vs
GLP-1 agonists have been used as a treatment for type 2 diabetes for nearly two decades
